"Cryptocurrency Concept Stocks Executive Interview" Huajian Medical: Reconstructing medical asset globalization with Web 3.0, launching a global enhanced Ether "ETH" treasury strategy.

Article Author: Echo Source: ME The Web 3.0 strategies and layouts of publicly listed companies have become a hot topic of increasing public interest. Against this backdrop, ME officially launches the "Cryptocurrency Concept Stock Executive Interview" series. We will engage in conversations with business leaders who dare to lead in the wave of digital transformation, delving into their strategic layouts, business innovations, and financial innovations through the first-person perspectives of decision-makers, providing forward-looking insights for industry participants.

On August 8, 2025, Hong Kong listed company Huajian Medical IVD MEDICAL (01931.HK) issued a series of significant announcements on the Hong Kong Stock Exchange, announcing a global strategic partnership with HashKey Exchange, the largest licensed virtual asset trading platform in Hong Kong, and completed the procurement of the first batch of 149.47 million Hong Kong dollars worth of Ethereum (ETH) reserves, officially launching the "Global Enhanced Ethereum 'ETH' Vault with Downside Protection Mechanism" strategy. In this interview, Gary Deng, Chief Strategy Officer of Huajian Medical IVD MEDICAL (01931.HK), gave us an in-depth explanation of how the company strategically balances the 'conservative' nature of the medical industry with the 'radical' world of Web 3.0. He shared the global enhanced Ethereum 'ETH' treasury strategy (referred to as the Ethereum 'ETH' treasury strategy) that Huajian Medical is promoting, which incorporates a downside protection mechanism, along with the ivd.xyz exchange ecosystem plan, aiming to open a new door for the globalization and capitalization of innovative drug assets. Not a "conflict", but a "complement": How does Web 3.0 address the real pain points in the healthcare industry? Is the healthcare industry conservative? Gary Deng believes the answer is no. "The healthcare industry has its traditional aspects, but it also has a more innovative side. It is inherently a high-demand, high-density, and highly compliant industry. Especially before the rise of AI, almost all breakthroughs relied on scientists—this industry is almost built on the foundation of PhDs." However, this characteristic also brings challenges. The development cycle for innovative drugs is extremely long, with an average investment of one billion dollars and nearly ten years required to complete the entire process from laboratory to commercialization. In recent years, the global financing environment has tightened, making it even more difficult for many small and medium-sized innovative drug companies. "They have many high-quality pipeline assets, the research and development has entered the mid-stage, and the product prospects are very good, but it is difficult to meet the listing requirements of Hong Kong Stock Exchange Chapter 18A and the thresholds of the NASDAQ and other markets, making it impossible to gain support from the global capital market," Gary Deng pointed out. On the other hand, the demand from large overseas pharmaceutical companies (such as Pfizer and Merck) for Chinese innovative drug assets is extremely strong. "In just the first half of this year, the amount of Chinese innovative drug pipeline licenses authorized overseas has reached nearly 70 billion dollars. But this is only a 'top-tier case' collaboration; the vast majority of small and medium-sized pharmaceutical companies have no opportunity to connect with the global market." It is this kind of supply and demand imbalance that has allowed Huajian Medical to see the integration opportunities brought by Web 3.0 and blockchain technology to the pharmaceutical industry. "Web 3.0 is not a contradictory existence, but a powerful complement. It can help traditional medical assets achieve better global allocation, which is the starting point of our strategic thinking." Dual-Engine Drive: Ethereum "ETH" Treasury Strategy + ivd.xyz Exchange Ecosystem The Web 3.0 strategy of Huajian did not come out of nowhere, but evolved step by step based on its industrial ecosystem as a listed company.

1. Ethereum "ETH" Treasury: Not just "holding", but "ecosystem feedback". Currently, Huajian Medical has obtained board approval for a budget of 880 million HKD to purchase Ethereum "ETH", and has already bought 149.47 million HKD. In the future, it will continue to increase its holdings through a "regular investment" method. More notably, the company is promoting a higher amount plan with a quota of 3 billion HKD, which is currently awaiting shareholder approval. Unlike many companies that simply "hold coins", Huajian Medical's Ethereum "ETH" treasury is an "enhanced version" - it is deeply integrated with the innovative drug RWA exchange ecosystem. "We will tokenize the innovative drug IP pipeline assets acquired or cooperated through the RWA exchange, and after promoting their development to a certain stage, sell them to global pharmaceutical companies or promote them for listing. The generated profits will be reinvested into the Ethereum "ETH" treasury; and the profits from Ethereum "ETH" itself will also be fed back into the acquisition of innovative drug assets—this forms a business closed loop."
2. Why Ethereum "ETH" and not Bitcoin? Gary Deng clearly responded: "We choose Ethereum 'ETH' because it aligns better with our industry attributes." As an industrial listed company, Huajian Medical must consider the integration of technology, ecology, and business. The Ethereum "ETH" smart contracts, DeFi, and asset issuance infrastructure can better support the tokenization and trading ecosystem of innovative drug IP, while Bitcoin currently still lacks such application adaptability. Who will become a user of the ivd.xyz exchange? How to lower the entry threshold? A practical question is: how can healthcare professionals, pharmaceutical scientists, and traditional investors—groups that are not familiar with blockchain—be attracted to Huajian Medical? Gary Deng stated that there are several key participants in the ivd.xyz exchange ecosystem:

• Asset issuers: that is, innovative pharmaceutical companies, especially small and medium-sized enterprises, that are willing to obtain financing and liquidity through asset tokenization;
• Platform Party: Huajian Medical and Exchange Ecosystem;
• Compliance service providers: auditors, law firms, regulatory bodies, etc.;
• Investors: including medical professional investment institutions, Web 3.0 native funds, and ordinary investors who will be allowed to enter under compliance in the future. "We do not expect every doctor or scientist to become a Web 3.0 user—they are more focused on scientific research itself. What we need to do is address their real needs: difficulty in financing, low asset liquidity, and high barriers to globalization." As for the popularization of education? Gary Deng appeared very composed: "The acceptance of new things always requires a process, but under the global wave of digitalization, it is just a matter of time. We will enable more people to understand and trust this mechanism through compliance, transparency, and gradual advancement." From Hong Kong to the world, Huajian Medical's ambitions have just begun. As a Hong Kong-listed company, Huajian Medical is currently actively promoting its secondary listing in the United States, which is in line with its globalization strategy. Gary Deng emphasized that Huajian Medical's goal is to become a benchmark for Ethereum "ETH" treasury reserves in the Hong Kong and even the Asian market, and to gradually occupy a place in the global Web 3.0 medical finance ecosystem. The weight of the healthcare industry and the agility of the Web 3.0 world are weaving an unprecedented picture in the strategy of Huajian Medical. Perhaps soon, we will see more traditional industry giants also beginning to rethink the future of assets, liquidity, and globalization with the same mindset.